Key points are not available for this paper at this time.
The paper considers the specifics of innovation activity and scientific and technological development in R the trends and persisting problems are studied. The potential of growth of domestic pharmaceutical industry with adequate interaction of state and business in entering the world markets was shown. It is pointed out that both abroad and in Russia during the pandemic the industry became one of the few where research costs had increased significantly. The paper shows that support policy for pharmaceutical industry in Russia over the next 10 years will be emphasized on the creation of own innovative drugs (including biotech types), and generics for the domestic market. The new ways of production and digitalization of the pharmaceutical industry remain outside the current support measures.
Ivanova et al. (Sat,) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: